m1A RNA Methylation Regulators Contribute To Malignant Progression And Have Clinical Prognostic Impact In Gliomas

Abstract

Background Glioma is the majority of primary malignant brain tumors in adults, accounting for over 70% of malignant brain tumors. RNA modification has been proved to be closely related to the development of various carcinomas including glioma. N1-methyladenosine (m1A) is a crucial and newly validated posttranscriptional modification in RNA. Its influence on glioma is still under elucidation. Results Gene expression and clinicopathological data of glioma were downloaded from TCGA and CGGA databases. The m1A regulators’ gene expression and its relationship with tumor malignancy grade or IDH mutation or 1p19q co-deletion status in glioma, as well as its related signaling pathway were investigated. We found that m1A regulators were dysregulated and positively associated with the WHO grade of glioma. The YTHDF2 expression was associated with the overall survival rate of glioma patients and was significantly lower in IDH mutation and the 1p/19q codeletion group. YTHDF2 mainly involved in RNA splicing, mRNA processing functions, or cell cycle relate pathways in glioma. Conclusion This study elucidated the dysregulation of m1A regulators and its potential signaling pathways in glioma, which will contribute to the further understanding of m1A RNA modification in glioma.